dr. kahl on the current treatment landscape in relapsed/refractory inhl
Published 3 years ago • 70 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
0:59
dr. kuruvilla on the treatment landscape in relapsed/refractory hodgkin lymphoma
-
1:42
dr. kahl on adct-402 for relapsed/refractory b-cell non-hodgkin lymphoma
-
37:22
eha 2024 recap: optimizing the relapsed/refractory cll treatment pathway
-
3:35
landscape change in the treatment of relapsed/refractory hcl
-
1:33
dr. kahl on the utility of tafasitamab/lenalidomide in dlbcl
-
29:00
dlbcl in 2023: top docs discuss the latest in diffuse large b-cell lymphoma | treatments & research
-
19:20
tony's non-hodgkin lymphoma story: going through cancer - again (relapse) | the patient story
-
7:51
relapsed/refractory mantle cell lymphoma
-
2:42
dr juckett on the evolving treatment paradigm in relapsed/refractory aml
-
6:08
relapsed/refractory dlbcl treatment landscape
-
1:49
dr. kahl discusses the construction of adcs for lymphoma treatment
-
4:32
how is relapsed/refractory dlbcl treated?
-
30:30
treatment of relapsed/refractory hodgkin's lymphoma
-
1:25
dr. kahl on remaining challenges in indolent non-hodgkin lymphoma
-
4:24
relapsed and refractory hodgkin lymphoma
-
1:53
dr. kahl on frontline btk inhibitor selection in cll
-
1:31
dr. kahl on efficacy of targeted agents in relapsed/refractory indolent lymphomas
-
2:03
dr. kahl on considerations for treatment strategies in cll
-
1:07
dr. kahl discusses the potential of frontline ibrutinib in mcl
-
5:33
management of refractory follicular lymphoma
-
4:07
author voices: brad kahl, md
-
0:15
copy of dr. kahl on patient preference in treatment selection for cll